By using mice models of both pancreatic neuroendocrine and cervical carcinoma, it has been demonstrated the ability of Sema3A to counteract the activation of HIF-1α and several hypoxia-dependent signalling pathways induced by sunitinib, an anti-angiogenic drug, with a consequent improvement of tumor tissue oxygenation. Here, HIF1A is linked to neoplasm.